Cargando…

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis

In ASTRAEA (NCT01860976), abatacept significantly increased American College of Rheumatology criteria 20% (ACR20) responses at Week 24 versus placebo in patients with psoriatic arthritis (PsA). This post hoc analysis explored relationships between prospectively identified baseline characteristics [p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mease, Philip J., McInnes, Iain B., Strand, Vibeke, FitzGerald, Oliver, Ahmad, Harris A., Elbez, Yedid, Banerjee, Subhashis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Clinical Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256096/ https://www.ncbi.nlm.nih.gov/pubmed/32356115 http://dx.doi.org/10.1007/s00296-020-04564-x

Ejemplares similares

Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial
por: McInnes, Iain B, et al.
Publicado: (2019)

Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial
por: Strand, Vibeke, et al.
Publicado: (2018)

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
por: Mease, Philip J, et al.
Publicado: (2017)

Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept
por: Ahmad, Harris A., et al.
Publicado: (2022)

Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
por: Mease, Philip, et al.
Publicado: (2016)

Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis
por: Szentpetery, Agnes, et al.
Publicado: (2017)

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
por: Mease, Philip J, et al.
Publicado: (2021)

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study
por: McInnes, Iain B., et al.
Publicado: (2018)

Synovial Tissue Response to Treatment in Psoriatic Arthritis
por: Codullo, Veronica, et al.
Publicado: (2011)

Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE study
por: Durez, Patrick, et al.
Publicado: (2022)

Abatacept in psoriatic arthritis: Case report and short review
por: Ursini, Francesco, et al.
Publicado: (2013)

Current treatment options for psoriatic arthritis: spotlight on abatacept
por: Ursini, Francesco, et al.
Publicado: (2018)

Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study
por: Alten, Rieke, et al.
Publicado: (2017)

Psoriatic arthritis: from pathogenesis to therapy
por: FitzGerald, Oliver, et al.
Publicado: (2009)

Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis
por: Helliwell, Philip, et al.
Publicado: (2014)

Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
por: Orbai, Ana-Maria, et al.
Publicado: (2022)

Early Origins of Psoriatic Arthritis: Clinical, Genetic and Molecular Biomarkers of Progression From Psoriasis to Psoriatic Arthritis
por: Pennington, Stephen R., et al.
Publicado: (2021)

Classification and Outcome Measures for Psoriatic Arthritis
por: Leung, Ying Ying, et al.
Publicado: (2018)

The many faces of psoriatic arthritis: their genetic determinism
por: Winchester, Robert, et al.
Publicado: (2020)

Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives
por: Noisette, Ashley, et al.
Publicado: (2018)

Psoriatic arthritis synovial histopathology: commentary on the article by Kruithof and colleagues
por: FitzGerald, Oliver
Publicado: (2005)

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis
por: van der Heijde, Désirée, et al.
Publicado: (2016)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
por: Ogdie, Alexis, et al.
Publicado: (2020)

Patient-Reported Outcomes and the Association With Clinical Response in Patients With Active Psoriatic Arthritis Treated With Golimumab: Findings Through 2 Years of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Kavanaugh, Arthur, et al.
Publicado: (2013)

Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis
por: Østergaard, Mikkel, et al.
Publicado: (2022)

Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set
por: Kalyoncu, Umut, et al.
Publicado: (2016)

Cutaneous lesions in psoriatic arthritis are enriched in chemokine transcriptomic pathways
por: Johnsson, Hanna, et al.
Publicado: (2023)

Treatment recommendations for psoriatic arthritis
por: Ritchlin, C T, et al.
Publicado: (2009)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2019)

Macrophage dysfunction in Psoriatic Arthritis
por: Wenink, Mark H, et al.
Publicado: (2011)

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
por: Mease, Philip J, et al.
Publicado: (2017)

Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype
por: FitzGerald, Oliver, et al.
Publicado: (2015)

Early biomarkers of joint damage in rheumatoid and psoriatic arthritis
por: Mc Ardle, Angela, et al.
Publicado: (2015)

Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials
por: Simon, Teresa A., et al.
Publicado: (2019)

Preface to the psoriatic arthritis supplement
por: Mease, Philip
Publicado: (2020)

Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
por: Mease, Philip J., et al.
Publicado: (2020)

Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study
por: Alten, Rieke, et al.
Publicado: (2016)

Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab
por: Wagner, Carrie L, et al.
Publicado: (2013)

Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2022)

Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies
por: Mease, Philip J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9h93p2kot5r975k7b5cj5s16gn